The discrediting of the monoamine hypothesis
Authors:
Open Access
- 1 February 2012
- journal article
- retracted article
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. 5, 135-142
Abstract
Background: The monoamine hypothesis has been recognized for over half a century as a reference point to understanding electrical dysfunction associated with disease states, and/or regulatory dysfunction related to synaptic, centrally acting monoamine concentrations (serotonin, dopamine, norepinephrine, and epinephrine). Methods: Organic cation transporters (OCT) are a primary force controlling intracellular and extracellular (including synaptic) concentrations of centrally acting monoamines and their amino acid precursors. A new type of research was analyzed in this paper (previously published by the authors) relating to determining the functional status of the nutritionally driven organic cation transporters. It was correlated with the claims of the monoamine hypothesis. Results: Results of laboratory assays from subjects not suffering from a hyperexcreting tumor show that centrally acting monoamine concentrations are indistinguishable in subjects with and without disease symptoms and/or regulatory dysfunction. Analysis of centrally acting monoamine concentrations in the endogenous state reveals a significant difference in day-to-day assays performed on the same subject with and without monoamine-related disease symptoms and/or regulatory dysfunction. The day-to-day difference renders baseline testing in the endogenous state non-reproducible in the same subject. Conclusion: It is asserted that the monoamine hypothesis, which claims that low synaptic levels of monoamines are a primary etiology of disease, is not a valid primary reference point for understanding chronic electrical dysfunction related to the centrally acting monoamines. Furthermore, the "bundle damage theory" is a more accurate primary model for understanding chronic dysfunction. The "bundle damage theory" advocates that synaptic monoamine levels are normal but not adequate in states associated with chronic electrical dysfunction and that levels need to be increased to compensate for the chronic postsynaptic electrical dysfunction due to existing damage. The monoamine hypothesis, in failing to accurately explain the etiology of chronic neuronal electrical flow dysfunction in the endogenous state, is reduced to no more than a historical footnote.Keywords
This publication has 18 references indexed in Scilit:
- Monoamine depletion by reuptake inhibitorsDrug, Healthcare and Patient Safety, 2011
- APRESS: apical regulatory super system, serotonin, and dopamine interactionNeuropsychiatric Disease and Treatment, 2011
- Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model”International Journal of Nephrology and Renovascular Disease, 2011
- Noradrenergic symptom cluster in depressionNeuropsychiatric Disease and Treatment, 2011
- Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrineResearch and Reports in Urology, 2011
- Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretationNeuropsychiatric Disease and Treatment, 2011
- Amino acid-responsive Crohn's disease: a case studyClinical and Experimental Gastroenterology, 2010
- A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive poleNeuropsychiatric Disease and Treatment, 2010
- Neurotransmitter testing of the urine: a comprehensive analysisResearch and Reports in Urology, 2010
- The molecular neurobiology of depressionNature, 2008